HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The Phase III programme, Enith1 and Enith2, is expected to launch this quarter
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The early-stage trial demonstrated an excellent safety profile alongside clinically meaningful improvements in visual acuity
Pangea will use its integrated validation platform and regulatory expertise to oversee analytical and clinical validation of Gene Solutions’ multi-omics technologies.
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
This innovation enhances viral stability, preserves potency, and reduces allergic reactions and antigen crystallisation-related issues
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
